Patents Examined by Karen Cochrane Carlson
  • Inducible eukaryotic expression system
    Patent number: 10696973
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Genetically modified bacterial cell factory for thiamine production
    Patent number: 10696992
    Abstract: The invention provides a genetically modified bacterium for production of thiamine; where the bacterium is characterized by a transgene encoding a thiamine monophosphate phosphatase (TMP phosphatase having EC 3.1.3.-) as well as transgenes encoding polypeptides that catalyze steps in the thiamine pathway. The genetically modified bacterium is characterized by enhanced synthesis and release of thiamine into the extracellular environment. The invention further provides a method for producing thiamine using the genetically modified bacterium of the invention; as well as the use of the genetically modified bacterium for extracellular thiamine production.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignee: BIOSYNTHIA APS
    Inventors: Luisa Gronenberg, Bo Salomonsen, Matteo Ferla, Hans Jasper Genee
  • Engineered DNase enzymes and use in therapy
    Patent number: 10696956
    Abstract: The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 30, 2020
    Assignee: NEUTROLIS, INC.
    Inventors: Tobias A. Fuchs, Miguel Jiménez-Alcázar, Josephine Göbel, Hanna Englert
  • Targeted antimicrobials and related compositions, methods and systems
    Patent number: 10688163
    Abstract: Targeted antimicrobials are described and related, compositions, methods and systems.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: June 23, 2020
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Paul J. Jackson, Brian E. Souza, Feliza A. Bourguet, Matthew A. Coleman
  • Targeted protein degradation
    Patent number: 10683360
    Abstract: The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: June 16, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Lewis Lee Brayshaw, Michael Menteith Hann, Christopher Herring, Carlos Martinez Fleites, Markus Alexander Queisser
  • Control of protein glycosylation by culture medium supplementation and cell culture process parameters
    Patent number: 10676772
    Abstract: The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 9, 2020
    Assignees: Biogen MA Inc., Samsung Bioepis
    Inventors: William C. Yang, Yao-Ming Huang, Kyle McElearney, Lia Tescione, James Lambropoulos, An Zhang, Valerie Liu Tsang, Thomas Ryll, Sangil Lee, Dae Sung Lee
  • Biological production of methyl methacrylate
    Patent number: 10676766
    Abstract: The invention relates to an engineered eukaryotic microorganism into which a gene encoding an acyl-CoA dehydrogenase is introduced and a method for producing methacrylic acid esters such as MMA and MMA-CoA and precursors thereof using the microorganism.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 9, 2020
    Assignees: The Regents of the University of California, Mitsubishi Chemical Corporation
    Inventors: Michelle O'Malley, Kevin Solomon, Wataru Mizunashi, Fujio Yu
  • Cell-permeable Cre (iCP-Cre) recombinant protein and use thereof
    Patent number: 10669531
    Abstract: The iCP-Cre recombinant protein of the present invention could mediate inactivation of a target genes, it may be used for the production of a conditional knockout mouse and be applied to investigation of the function and activation of the gene.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: June 2, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Identification of enzyme activity through determination of its localization
    Patent number: 10656158
    Abstract: A method of determining enzyme activity and identifying and classifying cellular targets, enzymatic pathways, and enzymatic agents involved in regulating metabolism in order to treat pathophysiological disorders. Monitoring enzyme activity is performed via a label-free bio cellular assay or fluorescence imaging. The identified and classified agents are used, together with a therapeutic agent, in the treatment of various metabolism-related diseases.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: May 19, 2020
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventor: Pablo Meyer Rojas
  • Vector co-expressing truncated von Willebrand factor and factor VIII
    Patent number: 10654911
    Abstract: The present invention relates to a co-expression vector that comprises both truncated von Williebrand Factor (vWF)-Fc DNA construct and B-domain deleted FVIII DNA construct in the same vector. By co-expressing FVIII and truncated vWF-Fc with one expression vector in cells, the present invention controls the ratio of gene templates for FVIII and vWF proteins, provides a higher protein ratio of FVIII to vWF during cell expression, that results in a better occupancy of FVIII in vWF, and creates a higher yield (>1000 IU/ml) and more stable expression of FVIII protein molecules. In one preferred embodiment, the truncated vWF contains mutations of cysteines in the D?D3 domain of vWF to reduce multimer assembly of recombinant vWF during expression, and thus increasing recovery and quality of FVIII.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: May 19, 2020
    Assignee: Beijing Neoletix Biological Technology Co., Ltd.
    Inventors: Qi Li, Hailong Zhang
  • Modulation of lipid metabolism for protein production
    Patent number: 10655111
    Abstract: The present disclosure features methods and compositions for modulating lipid metabolism to achieve improved production and quality of recombinant products, such as next generation biologics. Modulation of lipid metabolism as described herein includes, for example, introducing a lipid metabolism modulator described herein to a cell or a cell-free system. Also encompassed by the present disclosure are engineered cells with improved production capacity and improved product quality, methods for engineering such cells, and preparations and mixtures comprising the products from such cells.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: May 19, 2020
    Assignee: LONZA LTD.
    Inventors: James Budge, Christopher Mark Smales, Tanya Jeane Knight, Robert Young
  • Method for separation of monomeric polypeptides from aggregated polypeptides
    Patent number: 10654886
    Abstract: Herein is reported a method for obtaining a polypeptide in monomeric form comprising the steps of a) providing a solution comprising the polypeptide in monomeric form and in aggregated form, wherein the ratio of monomeric to aggregated form is 4:1 or less as determined by size exclusion chromatography, b) performing a mixed-mode chromatography in bind-and-elute mode, or a hydrophobic interaction chromatography in flow-through mode, or a size-exclusion chromatography, and c) performing a weak cation exchange chromatography in bind-and-elute mode or flow-through mode, and thereby obtaining the polypeptide in monomeric form.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 19, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Adelbert Grossmann, Stefan Hepbildikler
  • Method for producing N-acetylglucosamine by co-utilizing glucose and xylose based on CRISPRi
    Patent number: 10633658
    Abstract: The present invention discloses a method for producing N-acetylglucosamine (GlcNAc) by co-utilizing glucose and xylose based on CRISPRi, and belongs to the field of genetic engineering. According to the method, Bacillus subtilis BSGNY-Pveg-glmS-P43-GNA1 is used as an original strain, dCas9 induced by xylose and three sgRNA expression fragments targeting to genes zwf, pfkA and glmM respectively are integrated on the genome, and the strain is fermented in a shake flask, so that the titer of GlcNAc reaches 20.5 g/L, the yield of GlcNAc is 0.612 g/g glucose, at the same time, the efficient co-utilizing of glucose and xylose by the recombinant B.s subtilis is achieved, and the foundation for further metabolic engineering transformation of the B. subtilis to produce GlcNAc and industrialization thereof is laid.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: April 28, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Long Liu, Jian Chen, Guocheng Du, Jianghua Li, Yaokang Wu, Taichi Chen
  • Engineered CRISPR-Cas9 nucleases
    Patent number: 10633642
    Abstract: Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 28, 2020
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
  • Methods for genomic integration
    Patent number: 10626418
    Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: April 21, 2020
    Assignee: AMYRIS, INC.
    Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
  • Compositions and methods for treating pathological calcification and ossification
    Patent number: 10624958
    Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: April 21, 2020
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Compositions and methods for the treatment of hemoglobinopathies
    Patent number: 10619140
    Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
  • Methods for improved production of rebaudioside D and rebaudioside M
    Patent number: 10612066
    Abstract: Methods for recombinant production of steviol glycoside and compositions containing steviol glycosides are provided by this invention.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 7, 2020
    Assignee: Evolva SA
    Inventors: Michael Dalgaard Mikkelsen, Jorgen Hansen, Ernesto Simon, Federico Brianza, Angelika Semmler, Kim Olsson, Simon Carlsen, Louis Düring, Alexei Ouspenski, Paula Hicks
  • Thymidine kinase gene
    Patent number: 10610603
    Abstract: Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 7, 2020
    Assignee: GenVivo, Inc.
    Inventors: John P. Levy, Rebecca A. Reed, Joseph McNulty, Robert G. Johnson, Jr.
  • Method for producing C4 dicarboxylic acid
    Patent number: 10590442
    Abstract: Improvement in C4 dicarboxylic acid productivity in a host cell is provided. A polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 2 or an amino acid sequence having at least 90% identity therewith.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: March 17, 2020
    Assignee: Kao Corporation
    Inventors: Kyoshiro Nonaka, Fumikazu Takahashi